middle.news
How INOVIQ’s EXO-OC™ Test Could Revolutionize Early Ovarian Cancer Detection
10:01pm on Friday 29th of August, 2025 AEST
•
Healthcare
Read Story
How INOVIQ’s EXO-OC™ Test Could Revolutionize Early Ovarian Cancer Detection
10:01pm on Friday 29th of August, 2025 AEST
Key Points
FY25 net loss of $6.9 million with $6.5 million cash on hand
EXO-OC™ ovarian cancer test achieves 100% sensitivity for early-stage detection
CAR-NK-exosome therapy shows 88% in vitro cancer cell kill rate
Global expansion of EXO-NET® research tools via Promega partnership
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Inoviq (ASX:IIQ)
OPEN ARTICLE